35% Growth, 15% Guidance: A Record Quarter on Borrowed Margins

Q1 looks exceptional on paper: revenue +35.6%, PAT +173.9%, EBITDA a record ₹213 crores at 25.3% margin. Yet management walked off the call with FY27 guidance unchanged at 15-20% revenue growth. That gap—between a quarter that crushed and a full-year forecast that didn't budge—is the quarter's real message. On the call, management was transparent about why: the reported beat leans on temporary drivers. Low-cost inventory is being depleted, FX is favorable but reversible, and product mix shifted favorably. Once these normalize, gross margin will compress from 59.1% to the 55-56% sustainable range management guides. That's 300-400 basis points of downside sitting in the headline numbers. Management flagged it candidly. The question is whether Q2-Q4 will confirm it.

The real win is organic revenue: 35%+ growth excluding M&A, across all geographies. Europe's 53.1% organic growth ex-QliniQ is the standout. But the PAT surge of 173.9% is an artifact of temporary margin expansion. Once inventory normalizes and FX reverses, that margin compresses 300-400 bps. Management knew this on the call and said it plainly—which is why they held guidance despite being massively pressed to raise it.

The last claim needs scrutiny. At current run-rate, Marksans is tracking ~₹3,364 crores annualized from Q1. Hitting ₹4,000 Cr by FY28 (one year out) requires 19% CAGR—a step above their midpoint 17.5% FY27 guidance. Management reaffirmed the ₹4,000 Cr target but declined to raise near-term guidance, which suggests either hidden visibility into H2 acceleration, or the target is aspirational. Verdict: plausible but not committed. Europe M&A and the 3-5 year doubling vision are real, but contingent on execution and macro cooperation.

The stock's reaction post-result maps the analyst debate: day-1 disappointment, followed by re-rating once the margin drivers became clear.

At current levels (₹327 as of Aug 19), the stock sits 5.3% below its all-time high of ₹345.25, yet is up 111% from the 52-week low. RSI of 81.5 signals overbought technicals, but volume is increasing—no sign of distribution yet. The initial -2.94% reflects investor frustration that management didn't raise FY27 guidance despite the beat. By day 3, the bounce began as the market digested management's transparency on gross margin drivers and the 53%+ organic growth in Europe. The bounce held through day 5, suggesting institutional conviction that the underlying story (Europe breakout, organic momentum, long-term doubling) justifies the valuation despite near-term margin headwinds.

Foreign institutions are adding—a net positive signal on a quality, high-growth story. Domestic institutions trimmed marginally, possibly profit-taking or value-rotation bias. Promoter stake is steady at 43.87%; no insider selling near the highs. Bulk trades show Microcurves Trading as simultaneous buyer/seller at ₹313.24/₹313.40—a neutral crossing, not a red flag. Overall, institutional posture is net supportive of the long-term narrative.